0001209191-20-011040.txt : 20200220 0001209191-20-011040.hdr.sgml : 20200220 20200220161011 ACCESSION NUMBER: 0001209191-20-011040 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200218 FILED AS OF DATE: 20200220 DATE AS OF CHANGE: 20200220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Flynn Daniel Lee CENTRAL INDEX KEY: 0001713712 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38219 FILM NUMBER: 20635152 MAIL ADDRESS: STREET 1: C/O DECIPHERA PHARMACEUTICALS, LLC STREET 2: 500 TOTTEN POND ROAD CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001654151 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200299725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 781-209-6400 MAIL ADDRESS: STREET 1: 200 SMITH STREET CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC DATE OF NAME CHANGE: 20150928 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-02-18 0 0001654151 Deciphera Pharmaceuticals, Inc. DCPH 0001713712 Flynn Daniel Lee C/O DECIPHERA PHARMACEUTICALS, INC. 200 SMITH STREET WALTHAM MA 02451 0 1 0 0 Chief Scientific Officer Common Stock 2020-02-18 4 A 0 7040 0.00 A 98446 D Common Stock 91020 I By Daniel L. Flynn Irrevocable Trust Stock Option (Right to Buy) 54.87 2020-02-18 4 A 0 42190 0.00 D 2030-02-17 Common Stock 42190 42190 D The reporting person was awarded 7,040 Restricted Stock Units under the 2017 Stock Option and Incentive Plan. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in equal 25% installments on February 15, 2021, February 15, 2022, February 15, 2023 and February 15, 2024, subject to continued service through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments over a 4-year period following the vesting commencement date of 2/18/2020, subject to continued service through such dates. /s/ Thomas P. Kelly, Attorney-in-Fact 2020-02-20